Tenaya Therapeutics, Inc.
NASDAQ:TNYABiotechnology
-$0.00 today
- Market cap
- $69.95M
- Beta
- 2.82
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$0.54
Volume 2.77M
Average 3.79M
TNYA Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Tenaya Therapeutics, Inc.NASDAQ: TNYA
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow declines year over year
Q1 FY2026 free cash flow of $19.25M (cash outflow) fell 18.1% year over year, ahead of the -24.7% change in trailing-twelve-month free cash flow. Sequentially, it rose 37.4% from the prior quarter. Over 3 fiscal years it compounded at -18.0% a year.
Context
- Free cash flow grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -18.1% holds above the trailing-twelve-month pace of -24.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (68.88M) USD
- Year-over-year change
- +24.7%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (68.88M) | +24.7% |
| FY2024 | 2024-12-31 | (91.53M) | +11.4% |
| FY2023 | 2023-12-31 | (103.31M) | +17.4% |
| FY2022 | 2022-12-31 | (125.05M) | -45.5% |
| FY2021 | 2021-12-31 | (85.93M) | — |
Free Cash Flow vs competitors
How TNYA compares with its peers on the latest reported figures
- TNYA's LTM Mar 2026 free cash flow of $64.63M is the 7th largest of the 11 companies compared; the peer median is $76.11M.
- Its year-over-year change of -24.7% is the 8th highest of 11, against a peer median of -7.9%.
- Free cash flow amounts to 28725.3% of revenue for TNYA, versus a peer median of 419.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $129.94M | +14.0% | +108.0% | 356.1% | |
| LTM Mar 2026 | $102.38M | +1.6% | +13.6% | 5078.2% | |
| LTM Mar 2026 | $101.64M | -28.6% | +4.9% | 907.3% | |
| LTM Mar 2026 | $87.42M | -8.8% | — | 309.7% | |
| LTM Mar 2026 | $85.24M | +35.3% | +24.6% | 586.2% | |
| LTM Mar 2026 | $66.98M | +12.6% | -12.8% | 483.3% | |
| LTM Mar 2026 | $64.63M | -24.7% | -18.0% | 28725.3% | |
| LTM Mar 2026 | $51.43M | -12.1% | +2.6% | — | |
| LTM Mar 2026 | $49.91M | -7.0% | +0.5% | — | |
| LTM Mar 2026 | $43.78M | -58.6% | -13.4% | 261.8% | |
| LTM Mar 2026 | $9.61M | -88.3% | -28.2% | 13.9% | |
| Peer median (excluding TNYA) | $76.11M | -7.9% | +2.6% | 419.7% | |
Competitors are the stored peer set for TNYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (72.72M) | (123.67M) | (124.08M) | (111.13M) | (90.6M) |
| Depreciation & Amortization | 2.96M | 6.47M | 8.69M | 8.47M | 8.85M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.95M | 11.47M | 15.31M | 16.5M | 13.05M |
| Change in Working Capital | 4.74M | (849K) | (5.65M) | (7.93M) | (2.46M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 8.6M | 1.66M | (3.28M) | (581K) | (1.43M) |
| Other Working Capital | (3.86M) | (2.51M) | (2.37M) | (7.35M) | (1.03M) |
| Other Non-Cash Items | 1.26M | 2.16M | 3.66M | 3.59M | 2.9M |
| Operating Cash Flow | (60.81M) | (104.42M) | (102.07M) | (90.5M) | (68.26M) |
| Capital Expenditures | (25.12M) | (20.63M) | (1.24M) | (1.03M) | (618K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (213.44M) | (140.48M) | (56.64M) | (87.07M) | 0 |
| Sales of Investments | 0 | 244.75M | 106.62M | 89.21M | 56.7M |
| Other Investing Activities | 0 | 8K | (25K) | 17K | 0 |
| Investing Cash Flow | (238.56M) | 83.65M | 48.72M | 1.13M | 56.08M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 188.54M | 77.39M | 3.87M | 46.76M | 108.41M |
| Common Stock Repurchased | (13K) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 461K | 380K | 181K | 987K | 0 |
| Financing Cash Flow | 208.97M | 77.77M | 4.05M | 47.75M | 108.41M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (90.41M) | 57M | (49.31M) | (41.62M) | 96.22M |
| Free Cash Flow | (85.93M) | (125.05M) | (103.31M) | (91.53M) | (68.88M) |
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
Intrinsic Alpha fair value
Locked
Current Price
$0.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.